David Hogg, MD, FRCPC

Cancer genetics: melanoma and testicular cancer

The primary focus of my laboratory is cancer genetics. In collaboration with Norman Lassam (who tragically died in August, 2000) my laboratory described one of the first families with a germline mutation in the CDKN2A gene (Liu et al., Oncogene, 11: 405-412, 1995).

We went on to establish a program in inherited melanoma. The overall aim of the Toronto melanoma clinic is to utilize progress in cancer genetic research to focus preventative efforts on a population at high risk for this disease. We hypothesize that such directed surveillance will decrease morbidity and mortality from melanoma in the families and individuals under our care.

The Toronto melanoma program now comprises a clinic to identify and counsel families at risk; a clinical genetic laboratory dedicated to CDKN2A mutation testing; and a basic science program to characterize other genes that predispose to melanoma.

The clinic's multidisciplinary staff includes oncologists, dermatologists, nursing staff, plastic surgeons, a medical geneticist and social workers. Over the past four years, we have accrued over 200 melanoma families and have screened 170 of these kindreds for CDKN2A mutations (Liu et al., Nat Genet, 21: 128-132, 1999). We have also determined that a significant number of patients with multiple primary melanomas carry such mutations (Monzon et al., New Engl J Med, 338: 879-887, 1998).

My second major area of interest is the genetic basis of inherited and sporadic testicular germ cell cancer (Peng et al., Cancer Res, 55: 2871-2875, 1995; King et al., Cancer Res, 57: 209-214, 1997). I am also a member of the International Testicular Cancer Mapping Consortium. We recently published the first description of a testicular cancer susceptibility gene mapping to chromosome Xq27 (Rapley et al., Nat Genet, 24:197-200, 2000).
Lancet Oncol. 2018 Oct 18;:
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD
Melanoma Res. 2018 Jul 31;:
Nicholas MN, Khoja L, Atenafu EG, Hogg D, Quirt I, Butler M, Joshua AM
Clin Cancer Res. 2018 Jun 14;:
Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN
Ann Oncol. 2017 Oct 01;28(10):2581-2587
Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA
J Clin Oncol. 2017 Sep 15;:JCO2016721167
Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD
N Engl J Med. 2017 Sep 11;:
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C,...
Am J Kidney Dis. 2017 Jun 22;:
Kitchlu A, Fingrut W, Avila-Casado C, Chan CT, Crump M, Hogg D, Reich HN
Lancet Oncol. 2017 Jun 02;:
Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV
Lancet Oncol. 2017 Mar 08;:
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long...



Associate Professor, Department of Medical Biophysics, University of Toronto